CTOs on the Move

Dent Neurologic Institute

www.dentinstitute.com

 
The DENT Neurologic Institute is among the largest, most comprehensive neurology practices in the United States. We are focused on providing superior clinical care, advanced diagnostic services, clinical research, and education.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Spacelabs Healthcare

Spacelabs Healthcare is an American manufacturer of medical equipment and is a wholly owned subsidiary of OSI Systems of Hawthorne, California and offers products and services from three divisions: patient monitoring and connectivity, anesthesia delive...

Redox Pharmaceutical

Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CaptureRx

Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx solutions serve more than 500 hospitals and health centers in 45 states via a robust pharmacy network of more than 3,500 contracted locations of independent, national and regional pharmacies.

Rx Biotech Specialty Pharmacy

Rx Biotech Specialty Pharmacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).